Gout, diabetes and cardiovascular disease in the Aotearoa New Zealand adult population: Co-prevalence and implications for clinical practice

New Zealand Medical Journal

Volumn 126, Issue 1368, 2013, Pages 1-12

  Winnard, Doone ^a   Wright, Craig ^b   Jackson, Gary ^a   Gow, Peter ^c   Kerr, Andrew ^a   Mclachlan, Andrew ^a   Orr Walker, Brandon ^a   Dalbeth, Nicola ^a  

^a Manukau SuperClinic   (New Zealand)

^b MINISTRY OF HEALTH   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; DIABETES MELLITUS; DISEASE CLASSIFICATION; ETHNICITY; GOUT; HEALTH SERVICE; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MORTALITY; PATIENT REFERRAL; PRESCRIPTION; PREVALENCE;

EID: 84873489251     PISSN: 00288446     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Lindsay K, Gow P, Vanderpyl J, Logo P, Dalbeth N. The experience and impact of living with gout; a study of men with chronic gout using a qualitative grounded theory approach. Journal of Clinical Rheumatology 2011;17:1-6.
2. Kleinman N, Brook R, Patel P, et al. The impact of gout on work absence and productivity. Value Health 2007;10:231-7.
3. Dalbeth N, Collis J, Gregory K, Clark B, Robinson E, McQueen F. Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology 2007;46:1804-7.
4. Mikuls T, Saag K. New insights into gout epidemiology. Current Opinion in Rheumatology 2006;18:199-203.
5. Janssens H, van de Lisdonk E, Bor H, van den Hoogen H, Janssen M. Gout, just a nasty event or a cardiovascular signal? A study from primary care. Family Practice 2003;20:413-6.
6. Colvine K, Kerr A, McLachlan A, et al. Cardiovascular disease risk factor assessment and management in gout: an analysis using guideline-based electronic clinical decision support. New Zealand Medical Journal 2008;121:73-9.
7. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committtee for International Clinical Studies Including Therapeutics (ESCISIT). Annals of Rheumatic Disease 2006;65:1312-24.
8. Lennane G, Rose B, Isdale I. Gout in the Maori. Annals of Rheumatic Disease 1960;19:120-5.
9. Klemp P, Stansfield S, Castle B, Robertson M. Gout is on the increase in New Zealand. Annals of Rheumatic Disease 1997;56:22-6.
10. Taylor W, Smeets L, Hall J, McPherson K. The burden of rheumatic disorders in general practice: consultation rates for rheumatic disease and the relationship to age, ethnicity, and small-area deprivation. New Zealand Medical Journal 2004;117:1098.
11. Dalbeth N, Gow P. Prevention of colchicine toxicity in patients with gout New Zealand Medical Journal 2007;120:U2503.
12. Winnard D, Wright C, Taylor W, et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology 2012;doi: 10.1093/rheumatology/ker361.
13. Thornley S, Marshall R, Jackson G, et al. Estimating diabetes prevalence in South Auckland: how accurate is a method which combines lists of linked health data sets? New Zealand Medical Journal 2010;123:ISSN11758716.
14. Thornley S, Chan W-C, Crengle S, et al. Sociodemographic differences in prevalence of diagnosed coronary heart disease in New Zealand estimated from linked national health records. New Zealand Medical Journal 2011;124:ISSN 1175 8716.
15. Smith J, Jackson G, Orr-Walker B, et al. A population-based approach to the estimation of diabetes prevalence and health resource utilisation. New Zealand Medical Journal 2010;123:62-73.
16. Prior I, Rose B, Davidson F. Metabolic maladies in New Zealand Maoris British Medical Journal 1964;1:1065-69.
17. Robson B, Harris R, eds. Hauora. Maori standards of health IV. A study of the years 2000-2005. Wellington: Te Roopu Rangahau Hauora a Eru Pomare; 2007.
18. Wallace K, Riedel A, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. The Journal of Rheumatology 2004;31:1582-87.
19. Mikuls T, Farrar J, Bilker W, Fernandes S, Schumacher Jr H, Saag K. Gout epidemiology: Results form the UK General Practice Research Database, 1990-1999. Annals of Rheumatic Disease 2005;64:267-72.
20. Choi H, De Vera M, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology 2008;47:1567-70.
21. Dehghan A, van Hoek M, Sijbrands E, Hofman A, Witteman J. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 2008;31:361-2.
22. Fang J, Alderman M. Serum uric acid and cardiovascular mortaility. The NHANES 1 Epidemiologic Follow-up Study, 1971-1992. Journal of the American Medical Association 2000;283:2404-10.
23. Krishnan E, Baker J, Furst D, Schumacher H. Gout and the risk of acute myocardial infarction. Arthritis and Rheumatology 2006;54:2688-96.
24. Kim S, Guevara J, Kim K, Choi H, Heitjan D, Albert D. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis and Rheumatism 2009;61:885-92.
25. Kim S, Guevara J, Kim K, Choi H, Heitjan D, Albert D. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care & Research 2010;62:170-80.
26. Feig D, Kang D, Johnson R. Uric acid and cardiovascular risk. New England Journal of Medicine 2008;359:1811-21.
27. New Zealand Guidelines Group. New Zealand cardiovascular guidelines handbook: A summary resource for primary care practitioners. 2nd Ed. Wellington: New Zealand Guidelines Group; 2009.
28. Gibbons O, Merriman T. Update: Gout in the Maori community. Best Practice Journal 2008;13.
29. Gentles D, Metcalf P, Dyall L, et al. Metabolic syndrome prevalence in a multicultural population in Auckland, New Zealand. New Zealand Medical Journal 2007;120.
30. Lindstrom J, Ilanne-Parikka R, Peltonen M, Aunola S, Eriksson J, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention study. Lancet 2006;368:1673-79.
31. Dessein P, Shipton E, Stanwix A, et al. Beneficial effects of weight loss associated wtih moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and liprotein levels in gout: a pilot study. Annals of Rheumatic Disease 2000;59:539-43.
32. Liu Q, Gamble G, Pickering K, Morton S, Dalbeth N. Prevalence and clinical factors associated with gout in patients with diabetes and prediabetes. Rheumatology 2012;51(4):757-9.
33. Jackson G, Wright C, Thornley S et al. Potential unmet need for gout diagnosis and treatment: capture-recapture analysis of a national administrative dataset. Rheumatology 2012; doi:10.1093/rheumatology/kes147